# Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection

> **NCT05074394** · PHASE2 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** COVI-DROPS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05074394
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11
- **Primary completion:** 2022-11
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** to be replaced with a different protocol
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074394, "Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05074394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*